1,251 Shares in Solventum Co. (NYSE:SOLV) Purchased by Caisse Des Depots ET Consignations

Caisse Des Depots ET Consignations bought a new stake in Solventum Co. (NYSE:SOLV) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,251 shares of the company’s stock, valued at approximately $83,000.

A number of other hedge funds have also recently modified their holdings of the company. Worldquant Millennium Advisors LLC increased its position in shares of Solventum by 373.6% during the 3rd quarter. Worldquant Millennium Advisors LLC now owns 47,665 shares of the company’s stock worth $3,323,000 after purchasing an additional 37,600 shares during the last quarter. Harbor Capital Advisors Inc. grew its position in shares of Solventum by 24.8% during the fourth quarter. Harbor Capital Advisors Inc. now owns 46,965 shares of the company’s stock worth $3,103,000 after buying an additional 9,333 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Solventum by 37.4% during the third quarter. The Manufacturers Life Insurance Company now owns 117,853 shares of the company’s stock worth $8,217,000 after buying an additional 32,051 shares during the period. State Street Corp raised its holdings in Solventum by 3.1% in the third quarter. State Street Corp now owns 6,107,550 shares of the company’s stock valued at $425,818,000 after acquiring an additional 185,938 shares in the last quarter. Finally, Forsta AP Fonden purchased a new position in Solventum in the fourth quarter worth approximately $1,876,000.

Solventum Price Performance

SOLV stock opened at $74.78 on Friday. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. The company has a market capitalization of $12.94 billion and a P/E ratio of 27.19. The business has a 50 day simple moving average of $75.51 and a 200-day simple moving average of $71.83. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $85.92.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on SOLV shares. Bank of America lifted their price objective on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 26th. Piper Sandler upped their price objective on Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. Morgan Stanley raised their target price on Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 5th. Mizuho increased their price target on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, March 3rd. Finally, Wells Fargo & Company boosted their price objective on shares of Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Friday, February 28th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, Solventum presently has a consensus rating of “Hold” and an average target price of $79.86.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.